Quality of life in patients with various liver diseases: Patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages 252-261

  Tillmann, Hans L ^a,b   Wiese, M ^c,d   Braun, Y ^a   Wiegand, J ^e   Tenckhoff, S ^e   Mossner J ^e   Manns, M P ^a   Weissenborn, K ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Klinikum St Georg   (Germany)

^d Internistische Gemeinschaftspraxis   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Fatigue impact scale; HADS; Health related quality of life; Hepatitis B; Hepatitis C; PBC; PSC; SF36

Indexed keywords

INTERFERON;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BUDD CHIARI SYNDROME; DELTA AGENT HEPATITIS; FEMALE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NONALCOHOLIC FATTY LIVER; PHYSICAL DISEASE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; VIRAL CLEARANCE; VIREMIA; VIRUS REPLICATION; WILSON DISEASE;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; LIVER DISEASES; MALE; MENTAL HEALTH; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 79952676992     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01292.x     Document Type: Article

References (51)

1. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500. (Pubitemid 20015539)
2. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905. (Pubitemid 23006964)
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
4. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-96. (Pubitemid 30432371)
5. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-587.
6. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233. (Pubitemid 29181642)
7. Rai R, Wilson LE, Astemborski J et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002; 35: 1247-1255. (Pubitemid 34454022)
8. Wiese M, Grüngreiff K, Güthoff W et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005; 43(4): 590-598. (Pubitemid 41253225)
9. Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis 2004; 19(3-4): 351-356. (Pubitemid 39361193)
10. Forton DM, Allsop JM, Cox IJ et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 2005; 19(Suppl. 3): S53-S63. (Pubitemid 41682170)
11. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299-1301. (Pubitemid 29510870)
12. Barrett S, Goh J, Coughlan B et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001; 49(3): 423-430. (Pubitemid 32802579)
13. Tillmann HL, Kaiser T, Claes C, Schmidt RE, Manns MP, Stoll M. Differential influence of different hepatitis viruses on quality of life in HIV positive patients. Eur J Med Res 2006; 11(9): 381-385. (Pubitemid 44575698)
14. Ware JE, Sherbourne CD. The MOS 36- item short- form health survey (SF-36): 1. Conceptual framework and item selection. Med Care 1992; 30(6): 473-483.
15. Spiegel BMR, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41(4): 790-800. (Pubitemid 40462941)
16. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18(Suppl. 1): S79-S83. (Pubitemid 24023890)
17. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28(3): 551-558.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370. (Pubitemid 13098606)
19. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the anxiety and depression scale. An updated literature review. J Psychosom Res 2002; 52(2): 69-77. (Pubitemid 34192886)
20. Bondini S, Kallman J, Dan A et al. Health-related quality of life in patients with chronic hepatitis B. Liver Int 2007; 27(8): 1119-1125. (Pubitemid 47399447)
21. Sogolow ED, Lasker JN, Short LM. Fatigue as a major predictor of quality of life in women with autoimmune liver disease: the case of primary biliary cirrhosis. Womens Health Issues 2008; 18(4): 336-342.
22. Wong GL, Law FM, Wong VW et al. Health-related quality of life in Chinese patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2008; 23(4): 592-598. (Pubitemid 351501142)
23. ter Borg PC, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol 2004; 4: 13.
24. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009; 16(9): 605-611.
25. Carta MG, Hardoy MC, Garofalo A et al. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemol Ment Health 2007; 3(1): 22.
26. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
27. Martín-Santos R, Díez-Quevedo C, Castellví P et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008; 27(3): 257-265.
28. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 2682-2695. (Pubitemid 41007823)
29. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351(12): 1206-1217. (Pubitemid 39296307)
30. von Wagner M, Lee JH, Kronenberger B et al. Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. J Viral Hepat 2006; 13(12): 828-834. (Pubitemid 44748287)
31. Tsui JI, Bangsberg DR, Ragland K, Hall CS, Riley ED. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV. AIDS Behav 2007; 11(4): 603-610.
32. Helbling B, Overbeck K, Gonvers JJ et al. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57(11): 1597-1603.
33. Pattullo V, McAndrews M, Mrkonjic M, Damyanovich A, Heathcote E. Sustained virological response (SVR) to pegylated interferon and ribavirin has no effect on nuerocognition and cerebral metabolite levels in patients with chronic hepatitis C. IASL 2008. Hepatology 2008; 48 (Suppl.): 539A.
34. Maylin S, Martinot-Peignoux M, Moucari R et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135(3): 821-829.
35. Hoare M, Gelson WT, Rushbrook SM et al. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 2008; 48(6): 1737-1745.
36. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez- Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006; 194(1): 53-60.
37. Radkowski M, Horban A, Gallegos-Orozco JF et al. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 2005; 191(10): 1730-1733. (Pubitemid 40656762)
38. Fowell AJ, Sheron N, Rosenberg WM. Renal hepatitis C in the absence of detectable serum or hepatic virus. Liver Int 2008; 28(6): 889-891. (Pubitemid 351818652)
39. Thomopoulos K, Giannakoulas NC, Tsamandas AC et al. Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment. Am J Med Sci 2008; 336(1): 73-76.
40. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78(10): 5170-5183. (Pubitemid 38581469)
41. Letendre S, Paulino AD, Rockenstein E et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196(3): 361-370. (Pubitemid 47093886)
42. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 2009; 83(3): 1312-1319.
43. Collins JM, Riccardi R, Trown P, O'Neill D, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv 1985; 2(4): 247-253. (Pubitemid 16224559)
44. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985; 37(1): 85-88. (Pubitemid 16225171)
45. Nagai M, Arai T. Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 1984; 7(1): 55.
46. Kessel A, Toubi E. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr Med Chem 2007; 14(5): 547-554. (Pubitemid 46477727)
47. Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001; 16(3): 275-285.
48. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des 2008; 14(17): 1678-1685. (Pubitemid 351998592)
49. Mandl CW. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res 2005; 111(2): 161-174. (Pubitemid 40909734)
50. Solomon T, Winter PM. Neurovirulence and host factors in flavivirus encephalitis-evidence from clinical epidemiology. Arch Virol Suppl 2004; (18): 161-170.
51. Howard RS. Poliomyelitis and the postpolio syndrome. BMJ 2005; 330(7503): 1314-1318. (Pubitemid 40813566)